ArticleBMC neurology2023
The role of systemic ımmune ınflammatory ındex in showing active lesion ın patients with multiple sclerosis : SII and other inflamatuar biomarker in radiological active multiple sclerosis patients.
Article in BMC neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Association of HALP score with clinical and radiological activity following fingolimod discontinuation in patients with multiple sclerosis.eNeurologicalSci · 2026Article
- Systemic immune-inflammatory index is associated with malignancy in Lung-RADS 4 lung nodules.Journal of thoracic disease · 2026Article
- Association of Glycemic Status with Disability, Relapse Activity, Inflammatory Markers, and Metabolic Profile in Patients with Multiple Sclerosis.Journal of clinical medicine · 2026Article
- Association Between Inflammatory Cytokines and Systemic Inflammation Indices in Patients With Psoriasis: A Cross-Sectional Study.Health science reports · 2026Article
- Relationships Between the Corpus Callosum Index and Current Blood Parameters and Temporal Changes in these Parameters in Patients with Multiple Sclerosis.Neurosciences (Riyadh, Saudi Arabia) · 2026Article
- Predictors for the severity of acute aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorders: a prospective cohort study.Frontiers in immunology · 2026Article
- Comparative Analysis of Systemic Inflammatory Biomarkers Across Multiple Antiseizure Medications: A Single-Center Retrospective Cohort Study of 1782 Patients.Journal of clinical medicine · 2025Article
- Carotid intima media thickness, neutrophil to lymphocyte ratio, and platelet to lymphocyte ratio in multiple sclerosis.Scientific reports · 2025Article
- Carotid intima-media thickness and risk of atherosclerosis in multiple sclerosis: A cross-sectional study.PloS one · 2024Article
- Inflammatory and Nutritional Markers as Indicators for Diagnosing and Assessing Disease Activity in MS and NMOSD.Journal of inflammation research · 2024Article
- Development and validation of a peripheral cell ratio and lactate score for differentiating status epilepticus from prolonged psychogenic nonepileptic seizures.Epilepsia open · 2023Article
- A Preliminary Study on the Meaning of Inflammatory Indexes in MS: A Neda-Based Approach.Journal of personalized medicine · 2023Article
- Editorial: Bridging the gap between basic neurosciences and clinical neuroimmunology.Frontiers in neuroscience · 2023Article
- Predictive role of blood-based indicators in neuromyelitis optica spectrum disorders.Frontiers in neuroscience · 2023Article
- Anti-inflammatory Effect of Batroxobin Combined With Anticoagulation in Patients With Cerebral Venous Thrombosis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis (MS) has two pathophysiological processes, one inflammatory and the other degenerative. We investigated the relationship between active lesions on magnetic resonance imaging showing the inflammatory phase in MS patients and serum parameters that can be used as inflammatory biomarkers. Thus, we aim to detect the inflammatory period in clinical and radiological follow-up and to reveal the period in which disease-modifying treatments are effective with serum parameters.
methodsOne hundred eighty-six MS patients presented to our hospital between January 2016 and November 2021 and 94 age- and sex-matched healthy volunteers were recruited for our study. While 99 patients had active lesions on magnetic resonance imaging, 87 patients did not have any active lesions. Neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR) were determined. The SII (systemic immune inflammatory index) value was calculated according to the platelet X neutrophil/lymphocyte ratio formula.
resultsNLR, MLR, PLR and SII values were found to be statistically significantly higher in MS patients than in the control group. The NLR, MLR, PLR and SII were higher in the active group with gadolonium than in the group without active lesions. In addition, the cutoff values that we can use to determine the presence of active lesions were 1.53, 0.18, 117.15, and 434.45 for NLR, MLR PLR and SII, respectively.
conclusionsWe found that all parameters correlated with radiological activity. In addition, we showed that we can detect the inflammatory period with high sensitivity and specificity with the cutoff value used for SII and PLR. Among these easily accessible and inexpensive evaluations, we concluded that SII, including the values in the PLR formula, can come to the fore.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.